{"id":"menacwy-dt","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site pain"},{"rate":"10-15","effect":"Injection site erythema"},{"rate":"10-15","effect":"Injection site swelling"},{"rate":"20-30","effect":"Myalgia"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-10","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W, and Y, each conjugated to diphtheria toxoid (DT) as a carrier protein. This conjugation enhances immunogenicity by promoting T-cell dependent B-cell responses, resulting in stronger and more durable antibody production compared to unconjugated polysaccharide vaccines. The induced antibodies provide protection against invasive meningococcal disease caused by these four serogroups.","oneSentence":"MenACWY-DT is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by linking polysaccharide antigens to a diphtheria toxoid carrier protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:22.765Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y"}]},"trialDetails":[{"nctId":"NCT03694405","phase":"PHASE4","title":"Adolescent MenACWY Booster Study","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-09-20","conditions":"Meningococcal Disease, Invasive","enrollment":244}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Menactra"],"phase":"marketed","status":"active","brandName":"MenACWY-DT","genericName":"MenACWY-DT","companyName":"Canadian Immunization Research Network","companyId":"canadian-immunization-research-network","modality":"Biologic","firstApprovalDate":"","aiSummary":"MenACWY-DT is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by linking polysaccharide antigens to a diphtheria toxoid carrier protein. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}